Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors -

Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors

Eric Wickstrom (Herausgeber)

Buch | Hardcover
448 Seiten
1998
Crc Press Inc (Verlag)
978-0-8247-0085-0 (ISBN)
CHF 499,95 inkl. MwSt
A collection of clinical and preclinical reports on genetic therapy. It describes illustrative examples of diseases in which gene-based interventions are presently plausible, and presents case studies of research using both synthetic oligonucleotides and biological vectors. It also furnishes an historical overview of genetic therapy.
An important new collection of clinical and preclinical reports on genetic therapy, this book describes illustrative examples of diseases in which gene-based interventions are presently plausible, and presents case studies of current research using both synthetic oligonucleotides and biological vectors.
Combining the insights of over 50 contributors, Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors

furnishes a historical overview of genetic therapy

highlights official Food and Drug Administration positions on the preparation of oligonucleotides and vectors

offers practical models of agent preparation, animal testing, pharmacokinetics, toxicology, and clinical trials

discusses both synthetic DNA and biological vector approaches to cancer, viral, and cardiological indications

illustrates for new practitioners how each stage of genetic therapy is developed

details genetic treatment of leukemia; lymphoma; cancer of the brain, breast, colon, kidney, and lung; melanoma; HIV; and coronary restenosis

includes examples of antisense, ribozyme, tumor suppressor, immunostimulation, and gene replacement therapy

and addresses questions of preparation, delivery, toxicity, mechanism, and specificity.

Eric Wickstrom (Edited by)

A Brief History of Genetic Therapy: Gene Therapy, Antisense Technology, and Genomics, James W. Hawkins
Preclinical Development of Oligonucleotide Therapeutics for Cancer: Regulatory Aspects, Chang-Ho Ahn and Joseph J. DeGeorge
Commercial Scale Manufacturing of Oligonucleotides Under Good Manufacturing Practices, Jose E. Gonzalez, Richard G. Einig, Patricia Puma, Timothy P.Noonan, Paul E. Kennedy, Bruce G. Sturgeon, Bing H. Wang, and Jin-yan Tang
The Regulatory Process and Gene Therapy, Suzanne L. Epstein
Production of Clinical Lots of Gene Therapy Vectors Using Good Manufacturing Practice: Experience in a University Setting, Alan R. Davis and Colleen Baker
Gene Therapy Clinical Trials for Adenosine Deaminase Deficiency/Severe Combined Immunodeficiency, Erlinda M. Gordon and W. French Anderson
Development of an Oligodeoxynucleotide Pharmaceutical for the Treatment of Human Leukemia, Alan M. Gewirtz and Deborah Lee Sokol
Clinical Trials with Anti-p53 DNA, OL(1)p53, in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Patrick L. Iversen
Human Bcl-2 Antisense Therapy for Lymphomas, Finbarr E. Cotter, Andrew Webb, Paul Clarke, and David Cunningham
Retroviral Gene Transfer in Autologous Bone Marrow and Stem Cell Transplantation, Rafat Abonour and Kenneth Cornetta
Adenoviral Gene Transfer of the Herpes Virus Thymidine Kinase Gene for Treating Gliomas, Jane B. Alavi, Jason G. Smith, and Stephen L. Eck
Distribution and Toxicity of Retroviral Vectors After Intracavitary Delivery in Mouse and Man, Patrice S. Obermiller, Anne M. Pilaro, Carlos L. Arteaga, and Jeffrey T. Holt
Clinical and Immunologic Responses to Gene Transfer of an Allogeneic Major Histocompatibility Complex Antigen, Alison T. Stopeck and Evan M. Hersh
Defective Tumor Suppressor Gene Replacement and Oncogene Inactivation for the Treatment of Cancer, Jack Roth
The Molecular Basis of Bladder Cancer and Prospects for Gene Therapy Using Hammerhead Ribozymes, Eric J. Small, Mohammed Kashani-Sabet, David Y. Bouffard, and Kevin J. Scanlon
In Situ Gene Insertion for Immunotherapy Using Vaccinia Virus Vectors, Edmund C. Lattime, Laurence C. Eisenlohr, and Michael J. Mastrangelo
Antisense Oligonucleotide-Based Therapy for HIV-1 Infection from Laboratory to Clinical Trials, Sudhir Agrawal
Treatment of Retinitis Induced by Cytomegalovirus Using Intravitreal Fomivirsen (Isis 2922), Stanley T. Crooke
Synthetic DNA-Based Compounds for the Prevention of Coronary Restenosis: Current Status and Future Challenges, Andrew Zalewski, Yi Shi, John D. Mannion, and Fernando Roqué
Prevention of Restenosis by Gene Targeting, Michael J. Mann, Heiko E. Von der Leyen, and Victor J. Dzau

Erscheint lt. Verlag 21.4.1998
Verlagsort Bosa Roca
Sprache englisch
Maße 156 x 234 mm
Gewicht 952 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Studium 2. Studienabschnitt (Klinik) Humangenetik
Naturwissenschaften Biologie Genetik / Molekularbiologie
ISBN-10 0-8247-0085-6 / 0824700856
ISBN-13 978-0-8247-0085-0 / 9780824700850
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller

von Siddhartha Mukherjee

Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
CHF 30,75
Die revolutionäre Medizin von morgen (Lifespan)

von David A. Sinclair; Matthew D. LaPlante

Buch | Softcover (2020)
DuMont Buchverlag
CHF 22,40